Neuland Laboratories Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Neuland Laboratories de 9.2% y 9.3% por año respectivamente. Se prevé que el BPA crezca en un 9% al año. Se espera que la rentabilidad financiera sea de 21.6% en 3 años.
Información clave
12.2%
Tasa de crecimiento de los beneficios
11.9%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 17.0% |
| Tasa de crecimiento de los ingresos | 12.5% |
| Rentabilidad financiera futura | 21.5% |
| Cobertura de analistas | Low |
| Última actualización | 14 May 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12
Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Neuland Laboratories (NSE:NEULANDLAB) Has A Pretty Healthy Balance Sheet
Mar 15Can You Imagine How Elated Neuland Laboratories' (NSE:NEULANDLAB) Shareholders Feel About Its 391% Share Price Gain?
Feb 28Don't Ignore The Fact That This Insider Just Sold Some Shares In Neuland Laboratories Limited (NSE:NEULANDLAB)
Feb 12Neuland Laboratories Limited (NSE:NEULANDLAB) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 04Neuland Laboratories Limited's (NSE:NEULANDLAB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Feb 03Read This Before Selling Neuland Laboratories Limited (NSE:NEULANDLAB) Shares
Jan 18
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2027 | 22,719 | N/A | N/A | N/A | 1 |
| 3/31/2026 | 19,132 | 3,796 | 3,095 | 3,895 | 2 |
| 3/31/2025 | 15,980 | 3,017 | 2,938 | 3,316 | 2 |
| 3/31/2024 | 15,586 | 3,001 | 1,175 | 2,612 | N/A |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | 85 | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | 312 | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | 68 | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | -1,223 | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
| 3/31/2015 | 4,692 | 159 | N/A | 132 | N/A |
| 3/31/2014 | 4,657 | 268 | N/A | 488 | N/A |
| 12/31/2013 | 4,619 | 258 | N/A | 545 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (9.2% al año) de NEULANDLAB es superior a la tasa de ahorro (6.7%).
Beneficios vs. Mercado: Se prevé que los beneficios (9.2% al año) de NEULANDLAB crezcan menos que el mercado Indian (18% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de NEULANDLAB crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (11% al año) de NEULANDLAB crezcan más rápidamente que los del mercado Indian (9.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 9.3% al año) de NEULANDLAB crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de NEULANDLAB sea alta dentro de 3 años (21.6%)